GlaxoSmithKline is ready for a human clinical trial of HIV treatment as the boss launches a counterattack with activist investors
Counterattack: GSK Boss Emma Walmsley
GlaxoSmithKline is preparing to launch a human clinical trial of HIV treatment as his boss launches a counterattack with activist investors.
The British drug giant, hoping to start a groundbreaking trial next summer, today provides the city with the latest information on potential treatments for the disease.
This is the latest move in the GSK battle with activist investors. Earlier this month, the Daily Mail reported that when the UK approved another long-lasting HIV drug, signed a £ 734m deal for Covid treatment with the US, and gained EU support, the good news triple. Announced Whammy. Use that asthma jab further.
GSK CEO Dame Emma Walmsley wants to shake off activist investor Elliott Management.
Hedge funds have criticized GSK’s operation of the HIV business and “shrugged” from investors worried that they would “fall off the cliff” when the monopoly on one of the current drugs ends in the next eight years. It’s common. ” Year.
And Elliott says she’s targeting Walmsley, who wants to run GSK’s pharmaceutical business after she separates from the consumer sector, and she needs to reapply for work.
In today’s investor presentation, GSK’s HIV division Viiv seeks to prove its value by updating the progress of potential treatments.
GlaxoSmithKline is ready for human clinical trials for HIV treatment
Source link GlaxoSmithKline is ready for human clinical trials for HIV treatment